Identification

Name
Tubocurarine
Accession Number
DB01199  (APRD00176)
Type
Small Molecule
Groups
Approved
Description

A neuromuscular blocker and active ingredient in curare; plant based alkaloid of Menispermaceae. [PubChem]

Structure
Thumb
Synonyms
  • (+)-tubocurarine
  • 7',12'-Dihydroxy-6,6'-dimethoxy-2,2',2'-trimethyltubocuraranium
  • d-tubocurarine
  • Tubocurarin
Product Ingredients
IngredientUNIICASInChI Key
Tubocurarine chloride pentahydrate900961Z8VR6989-98-6WMIZITXEJNQAQK-GGDSLZADSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Tubocurarine Chloride Inj 3mg/mlSolution3 mgIntravenousAbbott1951-12-312008-06-06Canada
Tubocurarine Chloride Inj 3mg/ml USPSolution3 mgIntramuscular; IntravenousAbbott1985-12-312008-06-06Canada
International/Other Brands
Tubarine
Categories
UNII
W9YXS298BM
CAS number
57-95-4
Weight
Average: 609.7312
Monoisotopic: 609.296462054
Chemical Formula
C37H41N2O6
InChI Key
JFJZZMVDLULRGK-URLMMPGGSA-O
InChI
InChI=1S/C37H40N2O6/c1-38-14-12-24-19-32(42-4)33-21-27(24)28(38)16-22-6-9-26(10-7-22)44-37-35-25(20-34(43-5)36(37)41)13-15-39(2,3)29(35)17-23-8-11-30(40)31(18-23)45-33/h6-11,18-21,28-29H,12-17H2,1-5H3,(H-,40,41)/p+1/t28-,29+/m0/s1
IUPAC Name
(1S,16R)-9,21-dihydroxy-10,25-dimethoxy-15,15,30-trimethyl-7,23-dioxa-15,30-diazaheptacyclo[22.6.2.2³,⁶.1⁸,¹².1¹⁸,²².0²⁷,³¹.0¹⁶,³⁴]hexatriaconta-3,5,8(34),9,11,18(33),19,21,24,26,31,35-dodecaen-15-ium
SMILES
[H][[email protected]@]12CC3=CC=C(OC4=C5C(CC[N+](C)(C)[[email protected]]5([H])CC5=CC(OC6=C(OC)C=C(CCN1C)C2=C6)=C(O)C=C5)=CC(OC)=C4O)C=C3

Pharmacology

Indication

Used as a diagnosis agent for myasthenia gravis, and also to facilitate the intubation after induction of anesthesia in surgical procedure

Structured Indications
Not Available
Pharmacodynamics

Tubocurarine, a naturally occurring alkaloid, is used to treat smoking withdrawl syndrom.

Mechanism of action

Tubocurarine, the chief alkaloid in tobacco products, binds stereo-selectively to nicotinic-cholinergic receptors at the autonomic ganglia, in the adrenal medulla, at neuromuscular junctions, and in the brain. Two types of central nervous system effects are believed to be the basis of Tubocurarine's positively reinforcing properties. A stimulating effect is exerted mainly in the cortex via the locus ceruleus and a reward effect is exerted in the limbic system. At low doses the stimulant effects predominate while at high doses the reward effects predominate. Intermittent intravenous administration of Tubocurarine activates neurohormonal pathways, releasing acetylcholine, norepinephrine, dopamine, serotonin, vasopressin, beta-endorphin, growth hormone, and ACTH.

TargetActionsOrganism
ANeuronal acetylcholine receptor subunit alpha-2
antagonist
Human
A5-hydroxytryptamine receptor 3A
antagonist
Human
UAcetylcholinesterase
inhibitor
Human
UNeuronal acetylcholine receptor subunit alpha-7Not AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life

1-2 hours

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with 1,10-Phenanthroline.Experimental
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Tubocurarine.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Tubocurarine.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Tubocurarine.Experimental, Illicit
AcebutololTubocurarine may increase the bradycardic activities of Acebutolol.Approved
AcetylcholineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Acetylcholine.Approved
AcetyldigitoxinTubocurarine may increase the arrhythmogenic activities of Acetyldigitoxin.Approved
AcetyldigoxinTubocurarine may increase the arrhythmogenic activities of Acetyldigoxin.Experimental
AclarubicinAclarubicin may increase the respiratory depressant activities of Tubocurarine.Investigational
AclidiniumAclidinium may increase the anticholinergic activities of Tubocurarine.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Tubocurarine.Approved
AlcuroniumThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Alcuronium.Experimental
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Tubocurarine.Experimental
AlfentanilThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Alfentanil.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Alphaprodine.Illicit
AlprenololTubocurarine may increase the bradycardic activities of Alprenolol.Approved, Withdrawn
AmbenoniumThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Ambenonium.Approved
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Tubocurarine.Approved
AmikacinAmikacin may increase the respiratory depressant activities of Tubocurarine.Approved, Vet Approved
AmrubicinAmrubicin may increase the respiratory depressant activities of Tubocurarine.Approved, Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Androstenedione is combined with Tubocurarine.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Anecortave is combined with Tubocurarine.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Tubocurarine.Investigational
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Tubocurarine.Approved
annamycinannamycin may increase the respiratory depressant activities of Tubocurarine.Investigational
ApramycinApramycin may increase the respiratory depressant activities of Tubocurarine.Experimental, Vet Approved
ArbekacinArbekacin may increase the respiratory depressant activities of Tubocurarine.Approved
ArecolineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Arecoline.Experimental
ArotinololTubocurarine may increase the bradycardic activities of Arotinolol.Approved
AtamestaneThe risk or severity of adverse effects can be increased when Atamestane is combined with Tubocurarine.Investigational
AtenololTubocurarine may increase the bradycardic activities of Atenolol.Approved
AtracuriumThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Atracurium.Experimental
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Tubocurarine.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Tubocurarine.Approved, Vet Approved
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Tubocurarine.Approved, Investigational
BefunololTubocurarine may increase the bradycardic activities of Befunolol.Experimental
BekanamycinBekanamycin may increase the respiratory depressant activities of Tubocurarine.Experimental
BenactyzineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Benactyzine.Withdrawn
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Tubocurarine.Approved
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Tubocurarine.Approved
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Tubocurarine.Approved, Vet Approved
BetaxololTubocurarine may increase the bradycardic activities of Betaxolol.Approved
BethanecholThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Bethanechol.Approved
BevantololTubocurarine may increase the bradycardic activities of Bevantolol.Approved
BezitramideThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Bezitramide.Experimental, Illicit, Withdrawn
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Tubocurarine.Approved
BisoprololTubocurarine may increase the bradycardic activities of Bisoprolol.Approved
BopindololTubocurarine may increase the bradycardic activities of Bopindolol.Approved
BornaprineThe risk or severity of adverse effects can be increased when Bornaprine is combined with Tubocurarine.Experimental
Botulinum Toxin Type ABotulinum Toxin Type A may increase the neuromuscular blocking activities of Tubocurarine.Approved, Investigational
Botulinum Toxin Type BTubocurarine may increase the neuromuscular blocking activities of Botulinum Toxin Type B.Approved
BucindololTubocurarine may increase the bradycardic activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Tubocurarine.Approved
BufuralolTubocurarine may increase the bradycardic activities of Bufuralol.Experimental, Investigational
BumetanideBumetanide may decrease the neuromuscular blocking activities of Tubocurarine.Approved
BupranololTubocurarine may increase the bradycardic activities of Bupranolol.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Butorphanol.Approved, Illicit, Vet Approved
CapreomycinCapreomycin may increase the neuromuscular blocking activities of Tubocurarine.Approved
CarbacholThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Carbachol.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Carfentanil.Illicit, Vet Approved
CarteololTubocurarine may increase the bradycardic activities of Carteolol.Approved
CarvedilolTubocurarine may increase the bradycardic activities of Carvedilol.Approved, Investigational
CeliprololTubocurarine may increase the bradycardic activities of Celiprolol.Approved, Investigational
CevimelineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Cevimeline.Approved
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Tubocurarine.Approved, Vet Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Chlorphenoxamine.Withdrawn
ChlortetracyclineChlortetracycline may increase the neuromuscular blocking activities of Tubocurarine.Approved, Vet Approved
ChlorthalidoneThe serum concentration of Chlorthalidone can be increased when it is combined with Tubocurarine.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Tubocurarine.Approved, Investigational
CimetropiumTubocurarine may increase the anticholinergic activities of Cimetropium.Experimental
ClindamycinClindamycin may increase the neuromuscular blocking activities of Tubocurarine.Approved, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Clobetasol is combined with Tubocurarine.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Tubocurarine.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Clobetasone is combined with Tubocurarine.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Tubocurarine.Approved
CloranololTubocurarine may increase the bradycardic activities of Cloranolol.Experimental
CodeineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Codeine.Approved, Illicit
ColistimethateColistimethate may increase the neuromuscular blocking activities of Tubocurarine.Approved, Vet Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Cortexolone 17α-propionate is combined with Tubocurarine.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Corticosterone is combined with Tubocurarine.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Tubocurarine.Approved
CoumaphosThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Coumaphos.Vet Approved
CyclopenthiazideThe serum concentration of Cyclopenthiazide can be increased when it is combined with Tubocurarine.Experimental
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Tubocurarine.Approved
CyclosporineCyclosporine may increase the neuromuscular blocking activities of Tubocurarine.Approved, Investigational, Vet Approved
CymarinTubocurarine may increase the arrhythmogenic activities of Cymarin.Experimental
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Tubocurarine.Approved, Investigational
DaunorubicinDaunorubicin may increase the respiratory depressant activities of Tubocurarine.Approved
DecamethoniumThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Decamethonium.Approved
DemecariumThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Demecarium.Approved
DemeclocyclineDemeclocycline may increase the neuromuscular blocking activities of Tubocurarine.Approved
DeslanosideTubocurarine may increase the arrhythmogenic activities of Deslanoside.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Tubocurarine.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Tubocurarine.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Tubocurarine.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Tubocurarine.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Tubocurarine.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Tubocurarine.Vet Approved
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Tubocurarine.Withdrawn
DextromoramideThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Dezocine.Approved
DibekacinDibekacin may increase the respiratory depressant activities of Tubocurarine.Experimental
DichlorvosThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Dichlorvos.Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Tubocurarine.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Tubocurarine.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Tubocurarine.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Tubocurarine.Approved
DigitoxinTubocurarine may increase the arrhythmogenic activities of Digitoxin.Approved
DigoxinTubocurarine may increase the arrhythmogenic activities of Digoxin.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Dihydrocodeine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Dihydromorphine.Experimental, Illicit
DihydrostreptomycinDihydrostreptomycin may increase the respiratory depressant activities of Tubocurarine.Vet Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Diphenoxylate.Approved, Illicit
DipyridamoleThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Dipyridamole.Approved
DistigmineThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Distigmine.Experimental
DonepezilThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Donepezil.Approved
DoxorubicinDoxorubicin may increase the respiratory depressant activities of Tubocurarine.Approved, Investigational
DoxycyclineDoxycycline may increase the neuromuscular blocking activities of Tubocurarine.Approved, Investigational, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Tubocurarine is combined with DPDPE.Investigational
DronabinolTubocurarine may increase the tachycardic activities of Dronabinol.Approved, Illicit
EchothiophateThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Echothiophate.Approved
EdrophoniumThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Edrophonium.Approved
EluxadolineTubocurarine may increase the constipating activities of Eluxadoline.Approved
EmeproniumThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Emepronium.Experimental
EpanololTubocurarine may increase the bradycardic activities of Epanolol.Experimental
EpibatidineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Epibatidine.Experimental
EpirubicinEpirubicin may increase the respiratory depressant activities of Tubocurarine.Approved
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Tubocurarine.Experimental
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Tubocurarine.Approved
EsmololTubocurarine may increase the bradycardic activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Estrone is combined with Tubocurarine.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Tubocurarine.Approved
Etacrynic acidEtacrynic acid may decrease the neuromuscular blocking activities of Tubocurarine.Approved
EtanautineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Etanautine.Experimental
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Tubocurarine.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Ethylmorphine.Approved, Illicit
EtorphineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Etorphine.Illicit, Vet Approved
EtybenzatropineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Etybenzatropine.Experimental
FentanylThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenthionThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Fenthion.Vet Approved
FesoterodineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Fesoterodine.Approved
fluasteroneThe risk or severity of adverse effects can be increased when fluasterone is combined with Tubocurarine.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Tubocurarine.Approved
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Tubocurarine.Approved, Vet Approved
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Tubocurarine.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Tubocurarine.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Tubocurarine.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Tubocurarine.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Tubocurarine.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Tubocurarine.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Tubocurarine.Approved
FormestaneThe risk or severity of adverse effects can be increased when Formestane is combined with Tubocurarine.Approved, Investigational, Withdrawn
FramycetinFramycetin may increase the respiratory depressant activities of Tubocurarine.Approved
FurosemideFurosemide may decrease the neuromuscular blocking activities of Tubocurarine.Approved, Vet Approved
GalantamineThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Galantamine.Approved
GallamineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Gallamine.Experimental
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Tubocurarine.Approved
GeneticinGeneticin may increase the respiratory depressant activities of Tubocurarine.Experimental
GentamicinGentamicin may increase the respiratory depressant activities of Tubocurarine.Approved, Vet Approved
GENTAMICIN C1AGENTAMICIN C1A may increase the respiratory depressant activities of Tubocurarine.Experimental
Ginkgo bilobaThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Ginkgo biloba.Approved, Nutraceutical
GitoformateTubocurarine may increase the arrhythmogenic activities of Gitoformate.Experimental
Glucagon recombinantThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Glucagon recombinant.Approved
GlycopyrroniumTubocurarine may increase the anticholinergic activities of Glycopyrronium.Approved, Investigational, Vet Approved
GPX-150GPX-150 may increase the respiratory depressant activities of Tubocurarine.Investigational
GTS-21The risk or severity of adverse effects can be increased when Tubocurarine is combined with GTS-21.Investigational
HE3286The risk or severity of adverse effects can be increased when HE3286 is combined with Tubocurarine.Investigational
HeroinThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Heroin.Approved, Illicit
HexamethoniumThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Hexamethonium.Experimental
HomatropineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Homatropine.Approved
Huperzine AThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Huperzine A.Investigational
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Tubocurarine.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Hydrocodone.Approved, Illicit
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Tubocurarine.Approved, Vet Approved
HydroflumethiazideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Tubocurarine.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Hydromorphone.Approved, Illicit
Hygromycin BHygromycin B may increase the respiratory depressant activities of Tubocurarine.Vet Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Tubocurarine.Approved
IdarubicinIdarubicin may increase the respiratory depressant activities of Tubocurarine.Approved
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Tubocurarine.Approved
IndenololTubocurarine may increase the bradycardic activities of Indenolol.Withdrawn
INNO-206INNO-206 may increase the respiratory depressant activities of Tubocurarine.Investigational
IpidacrineThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Ipidacrine.Experimental
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Tubocurarine.Approved
IsepamicinIsepamicin may increase the respiratory depressant activities of Tubocurarine.Experimental
IsoflurophateThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Isoflurophate.Approved, Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Istaroxime is combined with Tubocurarine.Investigational
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Tubocurarine.Investigational
KanamycinKanamycin may increase the respiratory depressant activities of Tubocurarine.Approved, Vet Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Ketobemidone.Approved
LabetalolTubocurarine may increase the bradycardic activities of Labetalol.Approved
Lanatoside CTubocurarine may increase the arrhythmogenic activities of Lanatoside C.Experimental
LandiololTubocurarine may increase the bradycardic activities of Landiolol.Investigational
LevobunololTubocurarine may increase the bradycardic activities of Levobunolol.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Levomethadyl Acetate.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Levorphanol.Approved
LincomycinLincomycin may increase the neuromuscular blocking activities of Tubocurarine.Approved, Vet Approved
LithiumLithium may increase the neuromuscular blocking activities of Tubocurarine.Approved
LobelineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Lobeline.Investigational
LofentanilThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Lofentanil.Illicit
Magnesium HydroxideMagnesium Hydroxide may increase the neuromuscular blocking activities of Tubocurarine.Approved
Magnesium oxideMagnesium oxide may increase the neuromuscular blocking activities of Tubocurarine.Approved
Magnesium salicylateMagnesium salicylate may increase the neuromuscular blocking activities of Tubocurarine.Approved
Magnesium SulfateMagnesium Sulfate may increase the neuromuscular blocking activities of Tubocurarine.Approved, Vet Approved
MalathionThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Malathion.Approved, Investigational
MazaticolThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Mazaticol.Experimental
ME-609The risk or severity of adverse effects can be increased when ME-609 is combined with Tubocurarine.Investigational
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Tubocurarine.Approved
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Tubocurarine.Approved
MefloquineThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Mefloquine.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Tubocurarine.Vet Approved
MemantineThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Memantine.Approved, Investigational
MepindololTubocurarine may increase the bradycardic activities of Mepindolol.Experimental
MeptazinolThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Meptazinol.Experimental
MethacholineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Methacholine.Approved
MethadoneThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Methadyl Acetate.Approved, Illicit
Methanesulfonyl FluorideThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Methanesulfonyl Fluoride.Investigational
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Tubocurarine.Approved
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Tubocurarine.Approved
Methyl salicylateThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Methyl salicylate.Approved, Vet Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Tubocurarine.Approved, Vet Approved
MetildigoxinTubocurarine may increase the arrhythmogenic activities of Metildigoxin.Experimental
MetipranololTubocurarine may increase the bradycardic activities of Metipranolol.Approved
MetixeneThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Metixene.Approved
MetoclopramideThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Metoclopramide.Approved, Investigational
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Tubocurarine.Approved
MetoprololTubocurarine may increase the bradycardic activities of Metoprolol.Approved, Investigational
MetrizamideMetrizamide may increase the respiratory depressant activities of Tubocurarine.Approved
MianserinMianserin may increase the anticholinergic activities of Tubocurarine.Approved
MicronomicinMicronomicin may increase the respiratory depressant activities of Tubocurarine.Experimental
MinaprineThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Minaprine.Approved
MinocyclineMinocycline may increase the neuromuscular blocking activities of Tubocurarine.Approved, Investigational
MirabegronThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Mirabegron.Approved
MivacuriumTubocurarine may decrease the neuromuscular blocking activities of Mivacurium.Approved
MorphineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Morphine.Approved, Investigational
NabiloneTubocurarine may increase the tachycardic activities of Nabilone.Approved, Investigational
NadololTubocurarine may increase the bradycardic activities of Nadolol.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Nalbuphine.Approved
NCX 1022The risk or severity of adverse effects can be increased when NCX 1022 is combined with Tubocurarine.Investigational
NeamineNeamine may increase the respiratory depressant activities of Tubocurarine.Experimental
NeomycinNeomycin may increase the respiratory depressant activities of Tubocurarine.Approved, Vet Approved
NeostigmineThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Neostigmine.Approved, Vet Approved
NetilmicinNetilmicin may increase the respiratory depressant activities of Tubocurarine.Approved
NicomorphineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Nicomorphine.Experimental
NicotineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Nicotine.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Normethadone.Approved, Illicit
OleandrinTubocurarine may increase the arrhythmogenic activities of Oleandrin.Experimental
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Tubocurarine.Investigational
OpiumThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Opium.Approved, Illicit
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Tubocurarine.Approved
OtiloniumThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Otilonium.Experimental
OuabainTubocurarine may increase the arrhythmogenic activities of Ouabain.Approved
OxitropiumThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Oxitropium.Investigational
OxprenololTubocurarine may increase the bradycardic activities of Oxprenolol.Approved
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Tubocurarine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Tubocurarine.Approved
PancuroniumThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Pancuronium.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Tubocurarine.Approved
ParaoxonThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Paraoxon.Experimental
ParomomycinParomomycin may increase the respiratory depressant activities of Tubocurarine.Approved, Investigational
PenbutololTubocurarine may increase the bradycardic activities of Penbutolol.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Pentazocine.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Tubocurarine.Approved
PeruvosideTubocurarine may increase the arrhythmogenic activities of Peruvoside.Experimental
PethidineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Pethidine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Phenazocine.Experimental
PhenglutarimideThe risk or severity of adverse effects can be increased when Phenglutarimide is combined with Tubocurarine.Experimental
PhenoperidineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Phenoperidine.Experimental
PhysostigmineThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Physostigmine.Approved
PilocarpineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Pilocarpine.Approved
PindololTubocurarine may increase the bradycardic activities of Pindolol.Approved
PipecuroniumThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Pipecuronium.Approved
PirarubicinPirarubicin may increase the respiratory depressant activities of Tubocurarine.Investigational
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Tubocurarine.Approved
PiretanidePiretanide may decrease the neuromuscular blocking activities of Tubocurarine.Experimental
PiritramideThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Piritramide.Investigational
PirlimycinPirlimycin may increase the neuromuscular blocking activities of Tubocurarine.Vet Approved
PlazomicinPlazomicin may increase the respiratory depressant activities of Tubocurarine.Investigational
PlicamycinPlicamycin may increase the respiratory depressant activities of Tubocurarine.Approved, Withdrawn
Polymyxin B SulfatePolymyxin B Sulfate may increase the neuromuscular blocking activities of Tubocurarine.Approved, Vet Approved
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Tubocurarine.Approved
Potassium ChlorideTubocurarine may increase the ulcerogenic activities of Potassium Chloride.Approved, Withdrawn
PractololTubocurarine may increase the bradycardic activities of Practolol.Approved
PramlintidePramlintide may increase the anticholinergic activities of Tubocurarine.Approved, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Tubocurarine.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Tubocurarine.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Tubocurarine.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Tubocurarine.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Tubocurarine.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Tubocurarine.Experimental
ProcainamideProcainamide may increase the neuromuscular blocking activities of Tubocurarine.Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Tubocurarine.Approved
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Tubocurarine.Approved
PropiverineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Propiverine.Investigational
PropranololTubocurarine may increase the bradycardic activities of Propranolol.Approved, Investigational
ProscillaridinTubocurarine may increase the arrhythmogenic activities of Proscillaridin.Experimental
PuromycinPuromycin may increase the respiratory depressant activities of Tubocurarine.Experimental
PyridostigmineThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Pyridostigmine.Approved
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Tubocurarine.Approved
QuinidineQuinidine may increase the neuromuscular blocking activities of Tubocurarine.Approved
QuinineQuinine may increase the neuromuscular blocking activities of Tubocurarine.Approved
RamosetronTubocurarine may increase the constipating activities of Ramosetron.Approved
RapacuroniumTubocurarine may decrease the neuromuscular blocking activities of Rapacuronium.Withdrawn
RemifentanilThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Remifentanil.Approved
RibostamycinRibostamycin may increase the respiratory depressant activities of Tubocurarine.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Tubocurarine.Approved
RivastigmineThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Rivastigmine.Approved, Investigational
SabarubicinSabarubicin may increase the respiratory depressant activities of Tubocurarine.Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tubocurarine.Approved
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Scopolamine butylbromide.Approved, Vet Approved
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Tubocurarine.Approved, Investigational
SisomicinSisomicin may increase the respiratory depressant activities of Tubocurarine.Investigational
SolifenacinThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Solifenacin.Approved
SotalolTubocurarine may increase the bradycardic activities of Sotalol.Approved
SP1049CSP1049C may increase the respiratory depressant activities of Tubocurarine.Investigational
SpectinomycinSpectinomycin may increase the respiratory depressant activities of Tubocurarine.Approved, Vet Approved
StreptomycinStreptomycin may increase the respiratory depressant activities of Tubocurarine.Approved, Vet Approved
StreptozocinStreptozocin may increase the respiratory depressant activities of Tubocurarine.Approved
SuccinylcholineThe serum concentration of Succinylcholine can be increased when it is combined with Tubocurarine.Approved
SufentanilThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Sufentanil.Approved, Investigational
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Tubocurarine.Approved
TacrineThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Tacrine.Withdrawn
TalinololTubocurarine may increase the bradycardic activities of Talinolol.Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Tapentadol.Approved
TertatololTubocurarine may increase the bradycardic activities of Tertatolol.Experimental
TilidineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Tilidine.Experimental
TimololTubocurarine may increase the bradycardic activities of Timolol.Approved
TiotropiumTubocurarine may increase the anticholinergic activities of Tiotropium.Approved
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Tubocurarine.Approved
TobramycinTobramycin may increase the respiratory depressant activities of Tubocurarine.Approved, Investigational
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Tubocurarine.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Topiramate.Approved
TorasemideTorasemide may decrease the neuromuscular blocking activities of Tubocurarine.Approved
TramadolThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Tramadol.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Tubocurarine.Approved, Vet Approved
TrichlorfonThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Trichlorfon.Vet Approved
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Tubocurarine.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Tubocurarine.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Tubocurarine.Approved
TropatepineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Tropatepine.Experimental
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Tubocurarine.Approved
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Tubocurarine.Approved
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Tubocurarine.Approved
ValrubicinValrubicin may increase the respiratory depressant activities of Tubocurarine.Approved
VancomycinVancomycin may increase the neuromuscular blocking activities of Tubocurarine.Approved
VareniclineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Varenicline.Approved, Investigational
VecuroniumThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Vecuronium.Approved
Zoptarelin doxorubicinZoptarelin doxorubicin may increase the respiratory depressant activities of Tubocurarine.Investigational
ZorubicinZorubicin may increase the respiratory depressant activities of Tubocurarine.Experimental
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB15330
KEGG Compound
C07547
PubChem Compound
6000
PubChem Substance
46505279
ChemSpider
5778
BindingDB
50366799
ChEBI
9774
ChEMBL
CHEMBL339427
Therapeutic Targets Database
DAP000351
PharmGKB
PA451811
Wikipedia
Tubocurarine
ATC Codes
M03AA02 — Tubocurarine
MSDS
Download (73.2 KB)

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
SolutionIntravenous3 mg
SolutionIntramuscular; Intravenous3 mg
Prices
Unit descriptionCostUnit
Tubocurarine cl 3 mg/ml vial0.37USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000323 mg/mLALOGPS
logP3.12ALOGPS
logP3.14ChemAxon
logS-6.3ALOGPS
pKa (Strongest Acidic)6.45ChemAxon
pKa (Strongest Basic)8.12ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area80.62 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity187.06 m3·mol-1ChemAxon
Polarizability66.41 Å3ChemAxon
Number of Rings7ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.9757
Blood Brain Barrier+0.7287
Caco-2 permeable+0.6869
P-glycoprotein substrateSubstrate0.8917
P-glycoprotein inhibitor INon-inhibitor0.8855
P-glycoprotein inhibitor IINon-inhibitor0.8385
Renal organic cation transporterNon-inhibitor0.6081
CYP450 2C9 substrateNon-substrate0.8397
CYP450 2D6 substrateNon-substrate0.6012
CYP450 3A4 substrateSubstrate0.6597
CYP450 1A2 substrateNon-inhibitor0.9365
CYP450 2C9 inhibitorNon-inhibitor0.948
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9136
CYP450 3A4 inhibitorNon-inhibitor0.9284
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9794
Ames testNon AMES toxic0.5666
CarcinogenicityNon-carcinogens0.9195
BiodegradationNot ready biodegradable0.9401
Rat acute toxicity2.6331 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8786
hERG inhibition (predictor II)Non-inhibitor0.5444
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-03di-0000090000-3b12a16109f25ee30930
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-03di-0000090000-7ed720c5e8c5ce8facd3

Taxonomy

Description
This compound belongs to the class of organic compounds known as diarylethers. These are organic compounds containing the dialkyl ether functional group, with the formula ROR', where R and R' are aryl groups.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Ethers
Direct Parent
Diarylethers
Alternative Parents
Tetrahydroisoquinolines / Anisoles / Aralkylamines / Alkyl aryl ethers / 1-hydroxy-2-unsubstituted benzenoids / Tetraalkylammonium salts / Trialkylamines / Oxacyclic compounds / Azacyclic compounds / Organopnictogen compounds
show 3 more
Substituents
Diaryl ether / Tetrahydroisoquinoline / Anisole / Alkyl aryl ether / 1-hydroxy-2-unsubstituted benzenoid / Aralkylamine / Benzenoid / Tetraalkylammonium salt / Quaternary ammonium salt / Tertiary amine
show 12 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
benzylisoquinoline alkaloid (CHEBI:9774) / Isoquinoline alkaloids (C07547)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Drug binding
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name
CHRNA2
Uniprot ID
Q15822
Uniprot Name
Neuronal acetylcholine receptor subunit alpha-2
Molecular Weight
59764.82 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Wenningmann I, Dilger JP: The kinetics of inhibition of nicotinic acetylcholine receptors by (+)-tubocurarine and pancuronium. Mol Pharmacol. 2001 Oct;60(4):790-6. [PubMed:11562442]
  4. Nishimura K, Kitamura Y, Taniguchi T, Agata K: Analysis of motor function modulated by cholinergic neurons in planarian Dugesia japonica. Neuroscience. 2010 Jun 16;168(1):18-30. doi: 10.1016/j.neuroscience.2010.03.038. Epub 2010 Mar 23. [PubMed:20338223]
  5. Jonsson Fagerlund M, Dabrowski M, Eriksson LI: Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52. doi: 10.1097/ALN.0b013e31819fade3. [PubMed:19417616]
  6. Liu M, Dilger JP: Synergy between pairs of competitive antagonists at adult human muscle acetylcholine receptors. Anesth Analg. 2008 Aug;107(2):525-33. doi: 10.1213/ane.0b013e31817b4469. [PubMed:18633030]
  7. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Voltage-gated potassium channel activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gate...
Gene Name
HTR3A
Uniprot ID
P46098
Uniprot Name
5-hydroxytryptamine receptor 3A
Molecular Weight
55279.835 Da
References
  1. Hefft S, Hulo S, Bertrand D, Muller D: Synaptic transmission at nicotinic acetylcholine receptors in rat hippocampal organotypic cultures and slices. J Physiol. 1999 Mar 15;515 ( Pt 3):769-76. [PubMed:10066903]
  2. Yan D, White MM: Interaction of d-tubocurarine analogs with mutant 5-HT(3) receptors. Neuropharmacology. 2002 Sep;43(3):367-73. [PubMed:12243766]
  3. Yan D, Meyer JK, White MM: Mapping residues in the ligand-binding domain of the 5-HT(3) receptor onto d-tubocurarine structure. Mol Pharmacol. 2006 Aug;70(2):571-8. Epub 2006 May 24. [PubMed:16723497]
  4. Peters JA, Malone HM, Lambert JJ: Antagonism of 5-HT3 receptor mediated currents in murine N1E-115 neuroblastoma cells by (+)-tubocurarine. Neurosci Lett. 1990 Mar 2;110(1-2):107-12. [PubMed:1691468]
  5. Emerit MB, Riad M, Fattaccini CM, Hamon M: Characteristics of [14C]guanidinium accumulation in NG 108-15 cells exposed to serotonin 5-HT3 receptor ligands and substance P. J Neurochem. 1993 Jun;60(6):2059-67. [PubMed:7684066]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Serine hydrolase activity
Specific Function
Terminates signal transduction at the neuromuscular junction by rapid hydrolysis of the acetylcholine released into the synaptic cleft. Role in neuronal apoptosis.
Gene Name
ACHE
Uniprot ID
P22303
Uniprot Name
Acetylcholinesterase
Molecular Weight
67795.525 Da
References
  1. Radic Z, Taylor P: The influence of peripheral site ligands on the reaction of symmetric and chiral organophosphates with wildtype and mutant acetylcholinesterases. Chem Biol Interact. 1999 May 14;119-120:111-7. [PubMed:10421444]
  2. Golicnik M, Fournier D, Stojan J: Acceleration of Drosophila melanogaster acetylcholinesterase methanesulfonylation: peripheral ligand D-tubocurarine enhances the affinity for small methanesulfonylfluoride. Chem Biol Interact. 2002 Feb 20;139(2):145-57. [PubMed:11823003]
  3. Radic Z, Taylor P: Peripheral site ligands accelerate inhibition of acetylcholinesterase by neutral organophosphates. J Appl Toxicol. 2001 Dec;21 Suppl 1:S13-4. [PubMed:11920914]
  4. Gupta RC, Dettbarn WD: Potential of memantine, D-tubocurarine, and atropine in preventing acute toxic myopathy induced by organophosphate nerve agents: soman, sarin, tabun and VX. Neurotoxicology. 1992 Fall;13(3):649-61. [PubMed:1475066]
  5. Bianchi DA, Hirschmann GS, Theoduloz C, Bracca AB, Kaufman TS: Synthesis of tricyclic analogs of stephaoxocanidine and their evaluation as acetylcholinesterase inhibitors. Bioorg Med Chem Lett. 2005 Jun 2;15(11):2711-5. [PubMed:15878275]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Toxic substance binding
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The cha...
Gene Name
CHRNA7
Uniprot ID
P36544
Uniprot Name
Neuronal acetylcholine receptor subunit alpha-7
Molecular Weight
56448.925 Da
References
  1. Briggs CA, McKenna DG, Monteggia LM, Touma E, Roch JM, Arneric SP, Gopalakrishnan M, Sullivan JP: Gain of function mutation of the alpha7 nicotinic receptor: distinct pharmacology of the human alpha7V274T variant. Eur J Pharmacol. 1999 Feb 5;366(2-3):301-8. [PubMed:10082212]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Secondary active organic cation transmembrane transporter activity
Specific Function
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnico...
Gene Name
SLC22A1
Uniprot ID
O15245
Uniprot Name
Solute carrier family 22 member 1
Molecular Weight
61153.345 Da
References
  1. Busch AE, Quester S, Ulzheimer JC, Waldegger S, Gorboulev V, Arndt P, Lang F, Koepsell H: Electrogenic properties and substrate specificity of the polyspecific rat cation transporter rOCT1. J Biol Chem. 1996 Dec 20;271(51):32599-604. [PubMed:8955087]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Quaternary ammonium group transmembrane transporter activity
Specific Function
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creat...
Gene Name
SLC22A2
Uniprot ID
O15244
Uniprot Name
Solute carrier family 22 member 2
Molecular Weight
62579.99 Da
References
  1. Gorboulev V, Ulzheimer JC, Akhoundova A, Ulzheimer-Teuber I, Karbach U, Quester S, Baumann C, Lang F, Busch AE, Koepsell H: Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol. 1997 Jul;16(7):871-81. [PubMed:9260930]

Drug created on June 13, 2005 07:24 / Updated on October 02, 2017 04:54